314 related articles for article (PubMed ID: 26051947)
1. Platelets in patients with aspirin-exacerbated respiratory disease.
Laidlaw TM; Boyce JA
J Allergy Clin Immunol; 2015 Jun; 135(6):1407-14; quiz 1415. PubMed ID: 26051947
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of eosinophil apoptosis by asthma-relevant cytokines from platelets.
Varadharajan V
J Allergy Clin Immunol; 2015 Oct; 136(4):1134. PubMed ID: 26220528
[No Abstract] [Full Text] [Related]
3. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
Mitsui C; Kajiwara K; Hayashi H; Ito J; Mita H; Ono E; Higashi N; Fukutomi Y; Sekiya K; Tsuburai T; Akiyama K; Yamamoto K; Taniguchi M
J Allergy Clin Immunol; 2016 Feb; 137(2):400-11. PubMed ID: 26194538
[TBL] [Abstract][Full Text] [Related]
4. A trial of type 12 purinergic (P2Y
Laidlaw TM; Cahill KN; Cardet JC; Murphy K; Cui J; Dioneda B; Kothari P; Raby BA; Israel E; Boyce JA
J Allergy Clin Immunol; 2019 Jan; 143(1):316-324.e7. PubMed ID: 29890239
[TBL] [Abstract][Full Text] [Related]
5. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes.
Laidlaw TM; Kidder MS; Bhattacharyya N; Xing W; Shen S; Milne GL; Castells MC; Chhay H; Boyce JA
Blood; 2012 Apr; 119(16):3790-8. PubMed ID: 22262771
[TBL] [Abstract][Full Text] [Related]
6. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
Taniguchi M; Mitsui C; Hayashi H; Ono E; Kajiwara K; Mita H; Watai K; Kamide Y; Fukutomi Y; Sekiya K; Higashi N
Allergol Int; 2019 Jul; 68(3):289-295. PubMed ID: 31235242
[TBL] [Abstract][Full Text] [Related]
7. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease.
Choi JH; Kim MA; Park HS
Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):1-6. PubMed ID: 24300420
[TBL] [Abstract][Full Text] [Related]
8. Eosinophil production of prostaglandin D
Feng X; Ramsden MK; Negri J; Baker MG; Payne SC; Borish L; Steinke JW
J Allergy Clin Immunol; 2016 Oct; 138(4):1089-1097.e3. PubMed ID: 27423494
[TBL] [Abstract][Full Text] [Related]
9. Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
Steinke JW; Liu L; Huyett P; Negri J; Payne SC; Borish L
J Allergy Clin Immunol; 2013 Oct; 132(4):856-65.e1-3. PubMed ID: 23806637
[TBL] [Abstract][Full Text] [Related]
10. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Laidlaw TM; Buchheit KM; Cahill KN; Hacker J; Cho L; Cui J; Feng C; Chen CC; Le M; Israel E; Boyce JA
J Allergy Clin Immunol; 2023 Sep; 152(3):700-710.e3. PubMed ID: 37068712
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes.
Liu T; Laidlaw TM; Katz HR; Boyce JA
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16987-92. PubMed ID: 24085850
[TBL] [Abstract][Full Text] [Related]
12. Update on recent advances in the management of aspirin exacerbated respiratory disease.
Palikhe NS; Kim JH; Park HS
Yonsei Med J; 2009 Dec; 50(6):744-50. PubMed ID: 20046412
[TBL] [Abstract][Full Text] [Related]
13. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Lewis E; Gakpo D; Hacker J; Sohail A; Taliaferro F; Berreondo Giron E; Asare C; Vukovic M; Bensko JC; Dwyer DF; Shalek AK; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2021 Aug; 148(2):574-584. PubMed ID: 34144111
[TBL] [Abstract][Full Text] [Related]
14. Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity.
Liu T; Barrett NA; Kanaoka Y; Yoshimoto E; Garofalo D; Cirka H; Feng C; Boyce JA
J Immunol; 2018 Feb; 200(3):915-927. PubMed ID: 29282304
[TBL] [Abstract][Full Text] [Related]
15. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
[TBL] [Abstract][Full Text] [Related]
16. Aspirin-exacerbated respiratory disease.
Wangberg H; White AA
Curr Opin Immunol; 2020 Oct; 66():9-13. PubMed ID: 32299015
[TBL] [Abstract][Full Text] [Related]
17. Update on Aspirin-Exacerbated Respiratory Disease.
Woessner KM
Curr Allergy Asthma Rep; 2017 Jan; 17(1):2. PubMed ID: 28097500
[TBL] [Abstract][Full Text] [Related]
18. Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD.
Choi GS; Kim JH; Shin YS; Ye YM; Kim SH; Park HS
Clin Exp Allergy; 2013 Jul; 43(7):730-40. PubMed ID: 23786280
[TBL] [Abstract][Full Text] [Related]
19. Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
Laidlaw TM; Boyce JA
J Allergy Clin Immunol; 2023 Feb; 151(2):301-309. PubMed ID: 36184313
[TBL] [Abstract][Full Text] [Related]
20. Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.
Ledford DK; Wenzel SE; Lockey RF
J Allergy Clin Immunol Pract; 2014; 2(6):653-7. PubMed ID: 25439353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
